MiMedx (MDXG) Merger with Sanara MedTech Faces FTC Second Request, Extending Review

gurufocus.com · 2026-10-16

On October 16, 2026, MiMedx Group Inc (NASDAQ: MDXG) confirmed that the Federal Trade Commission (FTC) has issued a Second Request for additional information re

TickrTrends take: The FTC's second request regarding MiMedx's proposed merger with Sanara MedTech introduces regulatory uncertainty that could extend the timeline for deal completion and impact the combined entity's near-term financial trajectory. Given TickrTrends' current overvalued assessment of MDXG, investors should monitor whether prolonged regulatory review affects the company's ability to realize projected synergies or requires material adjustments to deal terms. The delayed merger resolution adds an additional risk factor to consider alongside the existing valuation concerns in the healthcare sector context.

Read the full story at gurufocus.com →